UCL Respiratory, University College London, London, United Kingdom.
Department of Respiratory Care, Prince Sultan Military College of Health Sciences, Dammam, Saudi Arabia.
PLoS One. 2020 May 11;15(5):e0233147. doi: 10.1371/journal.pone.0233147. eCollection 2020.
Coronavirus disease 2019 (COVID-19) is an evolving infectious disease that dramatically spread all over the world in the early part of 2020. No studies have yet summarized the potential severity and mortality risks caused by COVID-19 in patients with chronic obstructive pulmonary disease (COPD), and we update information in smokers.
We systematically searched electronic databases from inception to March 24, 2020. Data were extracted by two independent authors in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Study quality was assessed using a modified version of the Newcastle-Ottawa Scale. We synthesized a narrative from eligible studies and conducted a meta-analysis using a random-effects model to calculate pooled prevalence rates and 95% confidence intervals (95%CI).
In total, 123 abstracts were screened and 61 full-text manuscripts were reviewed. A total of 15 studies met the inclusion criteria, which included a total of 2473 confirmed COVID-19 patients. All studies were included in the meta-analysis. The crude case fatality rate of COVID-19 was 7.4%. The pooled prevalence rates of COPD patients and smokers in COVID-19 cases were 2% (95% CI, 1%-3%) and 9% (95% CI, 4%-14%) respectively. COPD patients were at a higher risk of more severe disease (risk of severity = 63%, (22/35) compared to patients without COPD 33.4% (409/1224) [calculated RR, 1.88 (95% CI, 1.4-2.4)]. This was associated with higher mortality (60%). Our results showed that 22% (31/139) of current smokers and 46% (13/28) of ex-smokers had severe complications. The calculated RR showed that current smokers were 1.45 times more likely [95% CI: 1.03-2.04] to have severe complications compared to former and never smokers. Current smokers also had a higher mortality rate of 38.5%.
Although COPD prevalence in COVID-19 cases was low in current reports, COVID-19 infection was associated with substantial severity and mortality rates in COPD. Compared to former and never smokers, current smokers were at greater risk of severe complications and higher mortality rate. Effective preventive measures are required to reduce COVID-19 risk in COPD patients and current smokers.
2020 年初,新型冠状病毒病 2019(COVID-19)是一种传染性极强的传染病,在全球范围内迅速蔓延。目前尚无研究总结 COVID-19 患者合并慢性阻塞性肺疾病(COPD)的潜在严重程度和死亡率风险,我们更新了吸烟者的相关信息。
我们系统地检索了从创建到 2020 年 3 月 24 日的电子数据库。两名独立的作者根据系统评价和荟萃分析的首选报告项目指南提取数据。使用纽卡斯尔-渥太华量表的改良版本评估研究质量。我们从合格研究中综合叙述性内容,并使用随机效应模型进行荟萃分析,以计算合并患病率和 95%置信区间(95%CI)。
共筛选出 123 篇摘要,审查了 61 篇全文。共有 15 项研究符合纳入标准,共纳入 2473 例确诊 COVID-19 患者。所有研究均纳入荟萃分析。COVID-19 的粗病死率为 7.4%。COVID-19 患者中 COPD 患者和吸烟者的合并患病率分别为 2%(95%CI,1%-3%)和 9%(95%CI,4%-14%)。与无 COPD 的患者(33.4%,409/1224)相比,COPD 患者发生更严重疾病的风险更高(严重程度风险=63%,22/35)[计算 RR,1.88(95%CI,1.4-2.4])。这与更高的死亡率(60%)相关。我们的结果显示,22%(31/139)的当前吸烟者和 46%(13/28)的前吸烟者有严重并发症。计算的 RR 显示,当前吸烟者发生严重并发症的可能性是前吸烟者和从不吸烟者的 1.45 倍[95%CI:1.03-2.04]。当前吸烟者的死亡率也更高,为 38.5%。
尽管目前报告 COVID-19 病例中 COPD 的患病率较低,但 COVID-19 感染与 COPD 患者的严重程度和死亡率密切相关。与前吸烟者和从不吸烟者相比,当前吸烟者发生严重并发症和更高死亡率的风险更大。需要采取有效的预防措施,降低 COPD 患者和当前吸烟者的 COVID-19 风险。